DAMAGE TO DOPAMINE SYSTEMS DIFFERS BETWEEN PARKINSONS-DISEASE AND ALZHEIMERS-DISEASE WITH PARKINSONISM
DAMAGE TO DOPAMINE SYSTEMS DIFFERS BETWEEN PARKINSONS-DISEASE AND ALZHEIMERS-DISEASE WITH PARKINSONISM
复制标题
DOI：
10.1002/ana.410370306
复制
发表时间：
1995-03-01
影响因子：
11.2
通讯作者：
JOYCE, JN
中科院分区：
文献类型：
--
作者：
MURRAY, AM;WEIHMUELLER, FB;JOYCE, JN
帕金森综合征发生在大约35%至40%的阿尔茨海默病（AD）患者中，即使在黑质中几乎没有或没有神经元变性，其在特发性帕金森病（PD）中导致纹状体多巴胺转运体位点的严重丧失。尚不清楚AD与帕金森综合征（AD/帕金森综合征）共存时是否存在纹状体多巴胺转运蛋白位点的丢失。我们将临床诊断为PD、AD和AD/帕金森综合征的患者的纹状体和中脑中的这些位点的模式与一组年龄匹配的对照受试者进行了量化。我们还定量的D2受体的数量和酪氨酸羟化酶的水平在黑质和腹侧被盖区的相同组。结果表明，在AD中多巴胺转运体位点的丢失仅限于延髓核。AD/帕金森综合征组中这些部位的丢失比AD组更广泛，尾状核和壳核的吻侧丢失最严重，尾状核和壳核的尾侧丢失最少。虽然PD组表现出同样严重的减少网站的数量，尾部到喙梯度的损失不同的AD/帕金森综合征组。PD组还表现出黑质和腹侧被盖区的多巴胺转运体位点、酪氨酸羟化酶和D2自身受体（位于多巴胺神经元上）的显著损失。相比之下，在AD或AD/帕金森综合征组的黑质和腹侧被盖区中未观察到多巴胺转运体位点、酪氨酸羟化酶和D2自身受体的减少。因此，纹状体多巴胺转运体位点的丢失可能与AD/帕金森综合征的临床症状有关。然而，这种损失不仅仅是黑质神经元变性的结果，而是必须来自其他过程。
Parkinsonism occurs in approximately 35 to 40% of patients with Alzheimer's disease (AD) even with little or no neuronal degeneration in the substantia nigra, which in idiopathic Parkinson's disease (PD) results in the severe loss of striatal dopamine transporter sites. It is not known if there is a loss of striatal dopamine transporter sites in AD with coexistent parkinsonism (AD/parkinsonism). We quantified the pattern of these sites in the striatum and midbrain of patients with the clinical diagnosis of PD, AD, and AD/parkinsonism in comparison with a group of age-matched control subjects. We also quantified the number of D2 receptors and the levels of tyrosine hydroxylase in the substantia nigra and ventral tegmental area of the same groups. The results showed that in AD the loss of dopamine transporter sites was restricted to the nucleus accumbens. The loss of these sites in the AD/parkinsonism group was more extensive than in the AD group, with the most severe losses in the rostral caudate and putamen and least in the caudal caudate and putamen. While the PD group showed an equally severe reduction in numbers of sites, the caudal to rostral gradient of loss differed from that in the AD/parkinsonism group. The PD group also showed a marked loss of dopamine transporter sites, tyrosine hydroxylase, and D2 autoreceptors (located on dopamine neurons) in the substantia nigra and ventral tegmental area. In contrast, no reductions in dopamine transporter sites, tyrosine hydroxylase, and D2 autoreceptors were observed in the substantia nigra and ventral tegmental area of the AD or AD/parkinsonism groups. Thus, the loss of striatal dopamine transporter sites in AD/parkinsonism may be related to the clinical parkinsonian symptoms. However, the loss is not simply the result of neuronal degeneration in the substantia nigra, but must derive from other processes.